Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013 (2013), Article ID 458989, 10 pages
Research Article

Characterization of Schizophrenia Adverse Drug Interactions through a Network Approach and Drug Classification

1Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
2Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA
3Mental Health Service Line, Washington VA Medical Center, 50 Irving St. NW, Washington, DC 20422, USA
4Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA
5Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
6Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Received 5 July 2013; Accepted 8 August 2013

Academic Editor: Bairong Shen

Copyright © 2013 Jingchun Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Antipsychotic drugs are medications commonly for schizophrenia (SCZ) treatment, which include two groups: typical and atypical. SCZ patients have multiple comorbidities, and the coadministration of drugs is quite common. This may result in adverse drug-drug interactions, which are events that occur when the effect of a drug is altered by the coadministration of another drug. Therefore, it is important to provide a comprehensive view of these interactions for further coadministration improvement. Here, we extracted SCZ drugs and their adverse drug interactions from the DrugBank and compiled a SCZ-specific adverse drug interaction network. This network included 28 SCZ drugs, 241 non-SCZs, and 991 interactions. By integrating the Anatomical Therapeutic Chemical (ATC) classification with the network analysis, we characterized those interactions. Our results indicated that SCZ drugs tended to have more adverse drug interactions than other drugs. Furthermore, SCZ typical drugs had significant interactions with drugs of the “alimentary tract and metabolism” category while SCZ atypical drugs had significant interactions with drugs of the categories “nervous system” and “antiinfectives for systemic uses.” This study is the first to characterize the adverse drug interactions in the course of SCZ treatment and might provide useful information for the future SCZ treatment.